File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Neutralizing antibody titres in SARS-CoV-2 infections

TitleNeutralizing antibody titres in SARS-CoV-2 infections
Authors
Issue Date2021
PublisherNature Research: Fully open access journals. The Journal's web site is located at http://www.nature.com/ncomms/index.html
Citation
Nature Communications, 2021, v. 12 n. 1, p. article no. 63 How to Cite?
AbstractThe SARS-CoV-2 pandemic poses the greatest global public health challenge in a century. Neutralizing antibody is a correlate of protection and data on kinetics of virus neutralizing antibody responses are needed. We tested 293 sera from an observational cohort of 195 reverse transcription polymerase chain reaction (RT-PCR) confirmed SARS-CoV-2 infections collected from 0 to 209 days after onset of symptoms. Of 115 sera collected ≥61 days after onset of illness tested using plaque reduction neutralization (PRNT) assays, 99.1% remained seropositive for both 90% (PRNT90) and 50% (PRNT50) neutralization endpoints. We estimate that it takes at least 372, 416 and 133 days for PRNT50 titres to drop to the detection limit of a titre of 1:10 for severe, mild and asymptomatic patients, respectively. At day 90 after onset of symptoms (or initial RT-PCR detection in asymptomatic infections), it took 69, 87 and 31 days for PRNT50 antibody titres to decrease by half (T1/2) in severe, mild and asymptomatic infections, respectively. Patients with severe disease had higher peak PRNT90 and PRNT50 antibody titres than patients with mild or asymptomatic infections. Age did not appear to compromise antibody responses, even after accounting for severity. We conclude that SARS-CoV-2 infection elicits robust neutralizing antibody titres in most individuals.
Persistent Identifierhttp://hdl.handle.net/10722/295734
ISSN
2021 Impact Factor: 17.694
2020 SCImago Journal Rankings: 5.559
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLau, EHY-
dc.contributor.authorTsang, OTY-
dc.contributor.authorHui, DSC-
dc.contributor.authorKwan, MYW-
dc.contributor.authorChan, WH-
dc.contributor.authorChiu, SS-
dc.contributor.authorKo, RLW-
dc.contributor.authorChan, KH-
dc.contributor.authorCheng, SMS-
dc.contributor.authorPerera, RAPM-
dc.contributor.authorCowling, BJ-
dc.contributor.authorPoon, LLM-
dc.contributor.authorPeiris, M-
dc.date.accessioned2021-02-08T08:13:14Z-
dc.date.available2021-02-08T08:13:14Z-
dc.date.issued2021-
dc.identifier.citationNature Communications, 2021, v. 12 n. 1, p. article no. 63-
dc.identifier.issn2041-1723-
dc.identifier.urihttp://hdl.handle.net/10722/295734-
dc.description.abstractThe SARS-CoV-2 pandemic poses the greatest global public health challenge in a century. Neutralizing antibody is a correlate of protection and data on kinetics of virus neutralizing antibody responses are needed. We tested 293 sera from an observational cohort of 195 reverse transcription polymerase chain reaction (RT-PCR) confirmed SARS-CoV-2 infections collected from 0 to 209 days after onset of symptoms. Of 115 sera collected ≥61 days after onset of illness tested using plaque reduction neutralization (PRNT) assays, 99.1% remained seropositive for both 90% (PRNT90) and 50% (PRNT50) neutralization endpoints. We estimate that it takes at least 372, 416 and 133 days for PRNT50 titres to drop to the detection limit of a titre of 1:10 for severe, mild and asymptomatic patients, respectively. At day 90 after onset of symptoms (or initial RT-PCR detection in asymptomatic infections), it took 69, 87 and 31 days for PRNT50 antibody titres to decrease by half (T1/2) in severe, mild and asymptomatic infections, respectively. Patients with severe disease had higher peak PRNT90 and PRNT50 antibody titres than patients with mild or asymptomatic infections. Age did not appear to compromise antibody responses, even after accounting for severity. We conclude that SARS-CoV-2 infection elicits robust neutralizing antibody titres in most individuals.-
dc.languageeng-
dc.publisherNature Research: Fully open access journals. The Journal's web site is located at http://www.nature.com/ncomms/index.html-
dc.relation.ispartofNature Communications-
dc.rightsNature Communications. Copyright © Nature Research: Fully open access journals.-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.titleNeutralizing antibody titres in SARS-CoV-2 infections-
dc.typeArticle-
dc.identifier.emailLau, EHY: ehylau@hku.hk-
dc.identifier.emailChiu, SS: ssschiu@hku.hk-
dc.identifier.emailKo, RLW: koronald@hku.hk-
dc.identifier.emailChan, KH: ra98466@hku.hk-
dc.identifier.emailCheng, SMS: samuelms@hku.hk-
dc.identifier.emailPerera, RAPM: mahenp@hku.hk-
dc.identifier.emailCowling, BJ: bcowling@hku.hk-
dc.identifier.emailPoon, LLM: llmpoon@hkucc.hku.hk-
dc.identifier.emailPeiris, M: malik@hkucc.hku.hk-
dc.identifier.authorityLau, EHY=rp01349-
dc.identifier.authorityChiu, SS=rp00421-
dc.identifier.authorityPerera, RAPM=rp02500-
dc.identifier.authorityCowling, BJ=rp01326-
dc.identifier.authorityPoon, LLM=rp00484-
dc.identifier.authorityPeiris, M=rp00410-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1038/s41467-020-20247-4-
dc.identifier.pmid33397909-
dc.identifier.pmcidPMC7782739-
dc.identifier.scopuseid_2-s2.0-85098668127-
dc.identifier.hkuros321158-
dc.identifier.volume12-
dc.identifier.issue1-
dc.identifier.spagearticle no. 63-
dc.identifier.epagearticle no. 63-
dc.identifier.isiWOS:000665627200039-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats